teduglutide

06/01/2020 - "As now (Gly2)GLP-2 is approved in the treatment of short bowel syndrome, we thought to investigate whether such molecule could be beneficial in bone fragility. "
02/14/2022 - "Teduglutide has been described as an effective treatment for parenteral support (PS) reduction in patients with short bowel syndrome (SBS). "
09/01/2009 - "In the treatment of short bowel syndrome, GLP-2 and the long-acting GLP-2 analogue teduglutide (Gattex) are effective in improving fluid absorption. "
02/14/2022 - "Efficacy of Teduglutide for Parenteral Support Reduction in Patients with Short Bowel Syndrome: A Systematic Review and Meta-Analysis."
01/01/2021 - "The aim of this study was to quantify the long-term clinical outcomes for individuals receiving teduglutide for short-bowel syndrome (SBS). "

03/01/2017 - "In a phase III trial in adults with SBS intestinal failure (IF) dependent on parenteral support (PS), a significantly greater proportion of teduglutide 0.05 mg/kg/day than placebo recipients achieved a ≥20% reduction in weekly PS volume from baseline to week 20 and maintained it to week 24. "
01/01/2023 - "This single-center study evaluated the safety and efficacy of teduglutide in pediatric patients with SBS-associated intestinal failure (SBS-IF). "
07/01/2013 - "Safety and efficacy of teduglutide after 52 weeks of treatment in patients with short bowel intestinal failure."
01/01/2020 - "Specialized intestinal failure units have recently reported their outcomes with teduglutide to evaluate if they are consistent with the phase III trials results. "
07/01/2018 - "The available data, albeit limited due to the small number of patients in the so-far performed studies, suggest that teduglutide appears to be safe to use in patients with intestinal failure who are dependent on parenteral support. "

12/01/2010 - "A phase II clinical trial for teduglutide in Crohn's disease observed remission rates of 55.6% in patients. "
07/01/2017 - "Because of the rarity of SBS, real-world safety or efficacy data are not available in patients with Crohn's disease (CD) and SBS treated with teduglutide. "
08/01/2013 - "Teduglutide in Crohn's disease."
01/01/2019 - "The first case had Crohn's disease (CD) with persistent colocutaneous fistulae that demonstrated complete closure after 8 months of teduglutide therapy. "
01/01/2017 - "Results of 12-month rescue treatment with Teduglutide in severely active and parenteral nutrition-dependent Crohn's disease."

01/01/2020 - "Patients treated with teduglutide experienced significantly greater reductions in SBS-QoL sum score at Week-24 vs placebo in 2 subgroups, ie, the third (highest) tertile baseline PS volume (-27.3, 95% CI: -50.8 to -3.7) and inflammatory bowel disease (IBD; -29.6, 95% CI: -46.3 to -12.9). "
01/01/2011 - "The reparative and immunomodulatory effects of teduglutide may also be beneficial in patients with inflammatory bowel disease (IBD). "
01/01/2018 - "Teduglutide had an intermediate effect on patients in group 3. A minority of patients with SBS and inflammatory bowel diseases had colon-in-continuity (10.5% [n = 2/19]), whereas most patients with SBS and vascular or other diseases had colon-in-continuity (84.4% [n = 27/32] and 67.6% [n = 23/34], respectively). "
08/01/2013 - "The literature search was performed using Medline database with the use of the following key words: teduglutide, glucagon-like peptide-2, CD and inflammatory bowel disease. "

06/01/2014 - "Body weight increment was similar for all 4 teduglutide groups but higher than placebo (P < 0.05). "
01/01/2010 - "The elimination half-life (t((1/2))) of teduglutide was also influenced by the body weight of participants. "
01/01/2010 - "Body weight was detected as a significant covariate explaining the volume of distribution of teduglutide. "
08/01/2023 - "Over the course of treatment with teduglutide, the patient was able to achieve independence from parenteral nutrition and experienced a significant improvement in quality of life (QoL) as stool frequency and consistency improved, urinary output was stabilized and body weight as well as body composition improved over the course of teduglutide therapy. "
01/01/2018 - "Co-treatment with exendin-4 and teduglutide rescued the body weight of the Tg mice and led to a hyperproliferation in the small intestine, whereas single treatment was less effective. "